Wegovy, Zepbound and similar medications all lead to metabolic improvements, but scientists are starting to unpick the ...

The market for weight-loss treatments is expected to see 16 new drugs vying for a slice of the lucrative business currently ...

Looking for successors to the blockbuster GLP-1 obesity drugs, companies like Novo Nordisk and Eli Lilly are testing amylin ...

Eli Lilly has launched a new website-based access programme for some drugs ... access obesity drugs, including WW International (formerly known as Weight Watchers), Found, and Noom, adding to ...

Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for ...

The widespread use and enormous expense of blockbuster drugs like Wegovy are forcing state governments to make painful ...

Morgan Stanley estimated that the global market for obesity drugs could increase by more than ... We've added you to our mailing list.

SYDNEY LUPKIN, BYLINE: Bill Coombs, who lives in Boston's South End, has lost 28 pounds so far on the obesity ... Drug Administration hasn't taken these drugs off its official shortage list.

The wave of new obesity drugs ... the FDA’s shortage list in 2022. They’ve been intermittently unavailable ever since. Shortages are a problem in part because these drugs must be taken consist ...

But does this new version of the drug come with its own costs? Zepbound is the latest drug to join the growing list of anti-obesity medications ... denied access to the essential treatment and ...

A dual GIP and GLP-1 receptor agonist, tirzepatide is the active ingredient used in the company’s two blockbuster medications — obesity ... study results add to the growing list of benefits ...

The branded drugs ... adding their names to the growing list of companies providing telehealth weight loss management and access to trendy GLP-1 medications. Analysts forecast that the obesity ...